Gro Linno Willemoe

Medicine & Life Sciences

1. Neoplasms 100%
2. Neoplasm Metastasis 99%
3. Adenocarcinoma 96%
4. Colorectal Neoplasms 89%
5. Liver 81%
6. Microsatellite Instability 56%
7. Liver Diseases 47%
8. Pancreatic Neoplasms 46%
9. Biomarkers 44%
10. Microvessels 41%
11. Survival 40%
12. Hepatocellular Carcinoma 37%
13. Caroli Disease 36%
14. Drug Therapy 36%
15. Glucagon-Like Peptide 2 36%
16. Elasticity Imaging Techniques 35%
17. Urokinase Plasminogen Activator Receptors 34%
18. Hemangioendothelioma 33%
19. Medullary Carcinoma 32%
20. Ipilimumab 32%
21. Nivolumab 31%
22. Appendix 30%
23. Hepatolenticular Degeneration 29%
24. Autoimmune Hepatitis 29%
25. Mutation 28%
26. Tetralogy of Fallot 28%
27. Perfusion 27%
28. Peroxisome Proliferator-Activated Receptors 27%
29. Fibrosis 27%
30. Tissue Inhibitor of Metalloproteinase-1 27%
31. Salvage Therapy 27%
32. Medical Oncology 27%
33. Macrophage Activation 26%
34. Anthracyclines 26%
35. Nasal Cavity 26%
36. Bevacizumab 25%
37. Radiosurgery 25%
38. Transforming Growth Factors 24%
39. Regulatory T-Lymphocytes 23%
40. Adjuvant Chemotherapy 23%
41. Staining and Labeling 23%
42. Glioblastoma 22%
43. Liver Cirrhosis 22%
44. T-Lymphocytes 21%
45. Proteolysis 21%
46. Heterografts 20%
47. Neuroendocrine Tumors 20%
48. Perfusion Index 20%
49. Promega 19%
50. Phenotype 19%